Skip to main content Back to Top
Advertisement

Guidelines and Publications

Additional Resources

Variety of other useful resources concerning drug-associated suicidality.

Guidelines

Joint Commission’s Sentinel Event Alert on Suicide (February 24, 2016)

FDA Medication Guides

ASHP’s REMS Resource Center — Contains information on the FDA’s post-marketing surveillance processes that are designed to ensure safety of all medications

FDA Reports

FDA updates information on Suicidal Behavior and Ideation and Antiepileptic Drugs – May 5, 2009

FDA issues Public Health Advisory to alert physicians of reports of suicidal thinking in children and adolescents associated with Strattera (atomoxetine) – September 29, 2005

FDA notifies healthcare professionals about the increased risks of suicidal thinking and behavior in young adults ages 18 to 24 years old during the first one to two months of antidepressant treatment – May 2, 2007

FDA issues Drug Safety Communication about revised description of mental health side effects of the stop-smoking drugs Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings – December 16, 2016

FDA provides healthcare professionals with updated information neuropsychiatric adverse events associated with leukotriene inhibitors (montelukast, zafirlukast and zileuton) – August 28, 2009

FDA notifies healthcare professionals of strengthened warnings for tramadol to emphasizes the risk of suicide for patients who are addiction-prone, taking tranquilizers or antidepressant drugs and also warns of the risk of overdosage – May 25, 2010

Publications

Drug-Induced Diseases: Prevention, Detection, and Management — Read Chapter 18 (Free) | Purchase a Book

AHFS Drug Information — Purchase a Book

Suicidality and risk of suicide — definition, drug safety concerns, and a necessary target for drug development: a consensus statement (PubMed)

Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials



Member Only

Join ASHP today to get access to the full content

JOIN ASHP

Resource Centers

Drug Shortages

Current Shortages

Current and resolved shortages, discontinued drugs and no commercially available preparations

Learn More
Link the whole card
AHFS® Clinical Drug Information

AHFS® Clinical Drug Information

AHFS® CDI is your comprehensive, interactive treatment and drug therapy solution.
Order Today
Link the whole card

About ASHP

We represent pharmacists who serve as patient care providers in acute and ambulatory settings.

Read More
Link the whole card

AHFS® Clinical Drug Information

AHFS® CDI is your comprehensive, interactive treatment and drug therapy solution.
Order Today
Link the whole card